Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Wave Life Sciences (WVE) over the last 10 years, with Q3 2025 value amounting to $46.5 million.

  • Wave Life Sciences' Current Deferred Revenue fell 6576.7% to $46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year decrease of 6576.7%. This contributed to the annual value of $66.0 million for FY2024, which is 5603.6% down from last year.
  • Wave Life Sciences' Current Deferred Revenue amounted to $46.5 million in Q3 2025, which was down 6576.7% from $51.6 million recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' Current Deferred Revenue registered a high of $150.1 million during Q4 2023, and its lowest value of $8.7 million during Q3 2021.
  • Over the past 5 years, Wave Life Sciences' median Current Deferred Revenue value was $51.6 million (recorded in 2025), while the average stood at $68.6 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 8986.45% in 2021, then skyrocketed by 37550.22% in 2023.
  • Wave Life Sciences' Current Deferred Revenue (Quarter) stood at $37.1 million in 2021, then fell by 14.93% to $31.6 million in 2022, then surged by 375.5% to $150.1 million in 2023, then tumbled by 56.04% to $66.0 million in 2024, then decreased by 29.48% to $46.5 million in 2025.
  • Its Current Deferred Revenue was $46.5 million in Q3 2025, compared to $51.6 million in Q2 2025 and $57.3 million in Q1 2025.